Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions

Summary

This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma for pediatric patients with underlying medical conditions (cardiovascular disease, lung disease, immunosuppression) who are either infected with SARS-CoV-2 or who have had a high-risk exposure. Study participants will be transfused once with compatible convalescent plasma obtained from an individual who has recovered from documented infection with SARS-CoV-2. Safety information and pharmacokinetic data will be collected.

Timeline

Start

2020-08

Primary completion

2024-09

Completion

2024-12

Drugs

Indications